RTW:LSE:LSE-RTW Venture Fund Ltd (USD)

COMMON STOCK | Asset Management |

Last Closing

USD 1.17

Change

0.00 (0.00)%

Market Cap

USD 38.52B

Volume

0.39M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Asset Management

Symbol Name Price(Change) Market Cap
FP:LSE Fondul Proprietatea S.A. GDR

N/A

USD 264.18B
MNTN:LSE Schiehallion Fund Ltd

+0.01 (+0.46%)

USD 96.99B
AMIF:LSE Amicorp FS (UK) PLC

+0.02 (+1.21%)

USD 19.19B
USF:LSE US Solar Fund Plc

N/A

USD 12.62B
MNG:LSE M&G Plc

+2.00 (+0.83%)

USD 5.61B
ICG:LSE Intermediate Capital Group PLC

+4.00 (+0.20%)

USD 5.60B
FCIT:LSE F&C Investment Trust PLC

-6.00 (-0.55%)

USD 5.16B
ABDN:LSE Abrdn PLC

+5.00 (+2.86%)

USD 2.81B
JGGI:LSE JP Morgan Global Growth & Inco..

N/A

USD 2.73B
PHLL:LSE Petershill Partners PLC

-1.50 (-0.70%)

USD 2.34B

ETFs Containing RTW:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Asset Management) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.13% 7% C- 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.13% 7% C- 13% F
Trailing 12 Months  
Capital Gain -17.89% 13% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.89% 13% F 18% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.75% 26% F 19% F
Dividend Return -5.75% 64% D 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.54% 82% B 43% F
Risk Adjusted Return -25.52% 62% D 21% F
Market Capitalization 38.52B 98% N/A 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector